PharmaCyte Biotech (PMCB) Total Liabilities (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Total Liabilities of $11.8 million for Q2 2026, up 259.21% year-over-year from $3.3 million in Q2 2025, and down 28.53% quarter-over-quarter from $16.5 million in Q1 2026.
PharmaCyte Biotech (PMCB) Total Liabilities (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Total Liabilities for 16 consecutive years, with $11.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 259.21% year-over-year to $11.8 million; the TTM figure through Apr 2026 stood at $11.8 million (up 259.21% YoY), while the FY2026 annual figure was $11.8 million, up 259.21% from the prior year.
- Total Liabilities fell to $11.8 million in Q2 2026 per PMCB's latest filing, from $16.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $22.5 million in Q1 2024 and bottomed at $586581.0 in Q2 2023.
- Historically, Total Liabilities has averaged $9.7 million across 5 years, with a median of $7.6 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities jumped 3375.95% — and 2025, when it tumbled 91.15%.
- PharmaCyte Biotech's Total Liabilities stood at $1.3 million in 2022, then jumped by 1487.38% to $20.8 million in 2023, then sank by 44.04% to $11.6 million in 2024, then surged by 66.76% to $19.4 million in 2025, then plunged by 39.39% to $11.8 million in 2026.
- Business Quant data shows PMCB's Total Liabilities at $11.8 million in Q2 2026, $16.5 million in Q1 2026, and $19.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 10.03 Bn |
| 10 | PharmaCyte Biotech | 4.36 Mn | 4.36 Mn | - | 11.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 11.77 Mn |
| Jan 31, 2026 | 16.47 Mn |
| Oct 31, 2025 | 19.42 Mn |
| Jul 31, 2025 | 1.52 Mn |
| Apr 30, 2025 | 3.28 Mn |
| Jan 31, 2025 | 3.58 Mn |
| Oct 31, 2024 | 11.65 Mn |
| Jul 31, 2024 | 17.15 Mn |
| Apr 30, 2024 | 20.39 Mn |
| Jan 31, 2024 | 22.47 Mn |
| Oct 31, 2023 | 20.81 Mn |
| Jul 31, 2023 | 20.40 Mn |
| Apr 30, 2023 | 586,581.00 |
| Jan 31, 2023 | 827,834.00 |
| Oct 31, 2022 | 1.31 Mn |
| Jul 31, 2022 | 1.09 Mn |
| Apr 30, 2022 | 704,370.00 |
| Jan 31, 2022 | 612,976.00 |
| Oct 31, 2021 | 186,122.00 |
| Jul 31, 2021 | 924,974.00 |